Showing 3391-3400 of 19337 results for "".
Knowing the Facts: Advance Directives and End-of-Life Care
https://reachmd.com/programs/advances-in-long-term-care-medicine/knowing-the-facts-advance-directives-and-end-of-life-care/6237/"Advance directive" is an umbrella term that encompasses end-of-life documents, including a living will and durable power of attorney for healthcare. Such documents can be scary for many patients, and as such, advance directives are not very common among the general US population. Yet these documentHealthy Aging: Promoting Well-being in Older Adults
https://reachmd.com/programs/grand-rounds-nation/healthy-aging-promoting-well-being-older-adults/9843/CDC experts discuss the impact the aging population will have on their caregivers, the public health system, and themselves.Fluid Biomarkers in Multiple Sclerosis
https://reachmd.com/diseases-diagnoses/ms-immune-disorders/fluid-biomarkers-in-multiple-sclerosis/36255/Fluid biomarkers may allow for improvement in diagnosis, prognostication, and monitoring of disease activity and treatment response in multiple sclerosis while reducing reliance on imaging.Enlisting Students in the Fight Against COVID-19: Helpful or Harmful?
https://reachmd.com/programs/covid-19-frontlines/enlisting-students-fight-against-covid-19-helpful-or-harmful/11325/Medical students are increasingly being thrust into frontline efforts to combat COVID-19. Will this help stem the tide, or compound the crisis?Novel Therapies in Managing Patients With Cardiovascular-Kidney-Metabolic Syndrome and Heart Failure
https://reachmd.com/clinical-practice/cardiology/novel-therapies-in-managing-patients-with-cardiovascular-kidney-metabolic-syndrome-and-heart-failure/35688/CKM syndrome and HFpEF overlap; discover how SGLT2i, GLP-1 RAs & nsMRAs offer a powerful approach to improve heart and kidney health.Beyond Steroidal MRAs: The Nonsteroidal MRA Lens in HF
https://reachmd.com/programs/cme/beyond-steroidal-mras-the-nonsteroidal-mra-lens-in-hf/49198/Examine how nonsteroidal MRAs inform risk-based treatment in HFpEF and HFmrEF, including stable patients with ongoing cardio-kidney-metabolic risk.Remnant Cholesterol: The Missing Link in ASCVD risk
https://reachmd.com/programs/cme/remnant-cholesterol-the-missing-link-in-ascvd-risk/33226/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.Spotlight on Europe: Adapting the Evidence
https://reachmd.com/programs/cme/spotlight-on-europe-adapting-the-evidence/39808/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.The Future of Oral SERDs: Combination Strategies
https://reachmd.com/programs/cme/the-future-of-oral-serds-combination-strategies/39801/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.FCS: Enhancing the Diagnosis
https://reachmd.com/programs/cme/fcs-enhancing-the-diagnosis/33220/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.